PUMA BIOTECHNOLOGY, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $26.66 million for the 25-month period ending 2012-09-30, per its 10-Q filed 2012-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2012-11-14
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-09-30 was $11.12M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-06-30 was $6.06M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-03-31 was $8.90M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2011-12-31 was $374.16K.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2011 was $586.21K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 16 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 18 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 21 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 25 month |
|---|---|---|---|---|---|---|---|---|
| 2012-09-30 | $11.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $17.18M derived: sum of 2 quarters · filed 2012-11-14 | $26.07M 10-Q · filed 2012-11-14 | $26.45M derived: sum of 4 quarters · filed 2012-11-14 | $26.66M 10-Q · filed 2012-11-14 | |||
| 2012-06-30 | $6.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $14.96M 10-Q · filed 2012-08-14 | $15.33M derived: sum of 3 quarters · filed 2012-08-14 | $15.54M 10-Q · filed 2012-08-14 | ||||
| 2012-03-31 | $8.90M 10-Q · filed 2012-05-15 | $9.27M derived: sum of 2 quarters · filed 2012-05-15 | $9.48M 10-Q · filed 2012-05-15 | |||||
| 2011-12-31 | $374.16K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-29 | $586.21K 10-K · filed 2012-03-29 | $586.21K 10-K · filed 2012-03-29 | |||||
| 2011-09-30 | $212.05K 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |